医学
颈动脉内膜切除术
无症状的
冲程(发动机)
狭窄
颈动脉
重症监护医学
血管外科
德国的
内科学
心脏外科
机械工程
历史
工程类
考古
作者
Kosmas I. Paraskevas,Dimitri P. Mikhailidis,Pier Luigi Antignani,Enrico Ascher,Hediyeh Baradaran,Reinoud P.H. Bokkers,Richard P. Cambria,Anthony J. Comerota,Alan Dardik,Alun H. Davies,Hans‐Henning Eckstein,Gianluca Faggioli,José Fernandes e Fernandes,Gustav Fraedrich,George Geroulakos,Péter Gloviczki,Jonathan Golledge,Ajay Gupta,Mateja K. Ježovnik,Stavros K. Kakkos
出处
期刊:Angiology
[SAGE Publishing]
日期:2022-04-12
卷期号:73 (10): 903-910
被引量:9
标识
DOI:10.1177/00033197221081914
摘要
Despite the publication of several national/international guidelines, the optimal management of patients with asymptomatic carotid stenosis (AsxCS) remains controversial. This article compares 3 recently released guidelines (the 2020 German–Austrian, the 2021 European Stroke Organization [ESO], and the 2021 Society for Vascular Surgery [SVS] guidelines) vs the 2017 European Society for Vascular Surgery (ESVS) guidelines regarding the optimal management of AsxCS patients. The 2017 ESVS guidelines defined specific imaging/clinical parameters that may identify patient subgroups at high future stroke risk and recommended that carotid endarterectomy (CEA) should or carotid artery stenting (CAS) may be considered for these individuals. The 2020 German–Austrian guidelines provided similar recommendations with the 2017 ESVS Guidelines. The 2021 ESO Guidelines also recommended CEA for AsxCS patients at high risk for stroke on best medical treatment (BMT), but recommended against routine use of CAS in these patients. Finally, the SVS guidelines provided a strong recommendation for CEA+BMT vs BMT alone for low-surgical risk patients with >70% AsxCS. Thus, the ESVS, German–Austrian, and ESO guidelines concurred that all AsxCS patients should receive risk factor modification and BMT, but CEA should or CAS may also be considered for certain AsxCS patient subgroups at high risk for future ipsilateral ischemic stroke.
科研通智能强力驱动
Strongly Powered by AbleSci AI